No Cover Image

Journal article 416 views 25 downloads

Incidence determinants and serological correlates of reactive symptoms following SARS-CoV-2 vaccination

Hayley Holt Orcid Logo, David A. Jolliffe, Mohammad Talaei Orcid Logo, Sian Faustini, Giulia Vivaldi Orcid Logo, Matthew Greenig, Alex G. Richter, Ronan Lyons Orcid Logo, Christopher J. Griffiths, Frank Kee, Aziz Sheikh, Gwyneth Davies Orcid Logo, Seif O. Shaheen, Adrian R. Martineau

npj Vaccines, Volume: 8, Issue: 1

Swansea University Authors: Ronan Lyons Orcid Logo, Gwyneth Davies Orcid Logo

  • 63120.pdf

    PDF | Version of Record

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.

    Download (574.83KB)

Abstract

Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the nat...

Full description

Published in: npj Vaccines
ISSN: 2059-0105
Published: Springer Science and Business Media LLC 2023
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa63120
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: Prospective population-based studies investigating associations between reactive symptoms following SARS-CoV-2 vaccination and serologic responses to vaccination are lacking. We therefore conducted a study in 9003 adults from the UK general population receiving SARS-CoV-2 vaccines as part of the national vaccination programme. Titres of combined IgG/IgA/IgM responses to SARS-CoV-2 spike (S) glycoprotein were determined in eluates of dried blood spots collected from all participants before and after vaccination. 4262 (47.3%) participants experienced systemic reactive symptoms after a first vaccine dose. Factors associating with lower risk of such symptoms included older age (aOR per additional 10 years of age 0.85, 95% CI: 0.81–0.90), male vs. female sex (0.59, 0.53–0.65) and receipt of an mRNA vaccine vs. ChAdOx1 nCoV-19 (0.29, 0.26–0.32 for BNT162b2; 0.06, 0.01–0.26 for mRNA-1273). Higher risk of such symptoms was associated with SARS-CoV-2 seropositivity and COVID-19 symptoms prior to vaccination (2.23, 1.78–2.81), but not with SARS-CoV-2 seropositivity in the absence of COVID-19 symptoms (0.94, 0.81–1.09). Presence vs. absence of self-reported anxiety or depression at enrolment associated with higher risk of such symptoms (1.24, 1.12–1.39). Post-vaccination anti-S titres were higher among participants who experienced reactive symptoms after vaccination vs. those who did not (P < 0.001). We conclude that factors influencing risk of systemic symptoms after SARS-CoV-2 vaccination include demographic characteristics, pre-vaccination SARS-CoV-2 serostatus and vaccine type. Participants experiencing reactive symptoms following SARS-CoV-2 vaccination had higher post-vaccination titres of IgG/A/M anti-S antibodies. Improved public understanding of the frequency of reactogenic symptoms and their positive association with vaccine immunogenicity could potentially increase vaccine uptake.
Keywords: Fever, Risk factors, RNA vaccines
College: Faculty of Medicine, Health and Life Sciences
Funders: Barts Charity
Issue: 1